Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib + Fulvestrant +/- Palbociclib in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer and Type 2 Diabetes
NCT07748208Phase 2Recruiting
- Sponsor
- Roche
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 2
01
Overview
A Phase 2 trial of inavolisib in breast cancer, sponsored by Roche. Started Oct 2026; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07748208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748208.